BioSpace News Archive

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumor infiltrating lymphocyte, TIL, and peripheral-blood lymphocyte, PBL), today announced the appointment of Wendy L. Dixon, Ph.D., to the company’s Board of Directors, effective June 10, 2022.

Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that its President and Chief Executive Officer, Ivor Royston , M.D., is being presented with the Science History Institute’s Biotechnology Heritage Award.

Innovent Biologics, Inc. and PT Etana Biotechnologies Indonesia, jointly announced that the Indonesian Food and Drugs Authority has approved Bevagen®, a recombinant humanized anti-VEGF monoclonal antibody drug, for five indications including metastatic colorectal cancer, locally recurrent or metastatic triple negative breast cancer, advanced, metastatic, or recurrent non-small cell lung cancer, epithelial ovarian, fallopian tube, and primary peritoneal cancer, and cervical cancer.

A new Health Trends® study from Quest Diagnostics developed in collaboration with the CDC found that the rate of hepatitis C antibody screening increased 145% in pregnant people during the decade-long study period ending June 2021.

BeiGene Announces BRUKINSA ™ (zanubrutinib) Is Approved in 50 Markets.

Amryt Presents Data for Mycapssa® (oral octreotide) from OPTIMAL and MPOWERED Phase 3 Trials at ENDO 2022.

Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate targeted T cells directly within the patient’s body, announced today that it will take part in a fireside chat at the JMP Securities Life Sciences Conference being held June 15–16, 2022.

Keros Therapeutics, Inc. today announced results from a preclinical study of RKER-012 on cardiac and pulmonary pathology in an established rodent model of pulmonary arterial hypertension (“PAH”).

SI-BONE, Inc. (SIBN), (Nasdaq: SIBN), a Silicon Valley-based medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced an FDA clearance for iFuse-TORQ ® for pelvic fracture fixation, including acute, non-acute and non-traumatic fractures.

Surrozen, Inc. today announced that the first subject has been dosed in its two-part Phase 1 clinical trial for SZN-043 which is in development for the potential treatment of severe alcoholic hepatitis.